Gleamer, a French startup company, has raised €27 million ($29.5 million) through a Series B round of funding, according to reports.
The five-year-old startup was responsible for developing AI software that helps radiologists diagnose and detect bone trauma lesions via scans among other conditions.
YOU MAY ALSO LIKE: Amazon Launches Amazon Web Services AppFabric
The company, which was founded in 2017, developed the BoneView software – its core flagship product – which it touts as an “AI companion for bone trauma x-rays”.
With help from the software, radiologists can be directed to portions of a scan that might be pointers to anomalies that the naked human eye can easily miss.
Gleamer also developed ChestView – another software used to detect pulmonary pathologies.
All of Gleamer’s software and related products have received certifications for use across Europe. BoneView has also received FDA clearance in the U.S.
The company boasts about 6,500 users located across 650 institutions in 24 countries.
Gleamer seeks to leverage a growing demand for medical imaging services, engineered in part by under-funded healthcare systems, an increasing number of chronic diseases, and aging populations.
Just last week, the U.K. Government announced a new £21 million fund to drive AI deeper into the NHS, with medical imaging as one of the main targets.
Meanwhile, several startups have raised large amounts of venture capital (VC) funding to introduce new services and technologies to the radiology sector.
Some of which include private medical imaging marketplaces, portable x-ray machines, and so-called “decision support” software powered by AI.
Gleamer has now raised a €36 million in total since its inception, and with its latest cash input, it said that it has plans to extend its product portfolio to include mammography and CT scans.
YOU MAY ALSO LIKE: Prosus Slashes Its Stake Valuation At Byju’s To $5.1 Billion
The Paris-based company is also seeking to expand its team both in the United States and Europe. Gleamer’s Series B round was co-led by Heal Capital and Supernova Invest.
Some of the participants were XAnge, MACSF, Elaia, F3A, Bpifrance, Crista Galli Ventures, and several radiologists across Europe.
